Literature DB >> 22520975

Therapeutic antibodies against cancer.

Mark J Adler1, Dimiter S Dimitrov.   

Abstract

Antibody-based therapeutics against cancer are highly successful and currently enjoy unprecedented recognition of their potential; 13 monoclonal antibodies (mAbs) have been approved for clinical use in the European Union and in the United States. Bevacizumab, rituximab, and trastuzumab had sales in 2010 of more than $5 billion each. Hundreds of mAbs, including bispecific mAbs and multispecific fusion proteins, mAbs conjugated with small-molecule drugs, and mAbs with optimized pharmacokinetics, are in clinical trials. However, deeper understanding of mechanisms is needed to overcome major problems including resistance to therapy, access to targets, complexity of biological systems, and individual variations.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22520975      PMCID： PMC3334873          DOI： 10.1016/j.hoc.2012.02.013

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  228 in total

1.  Responsiveness to cetuximab without mutations in EGFR.

Authors:  Zenta Tsuchihashi; Shirin Khambata-Ford; Nasser Hanna; Pasi A Jänne
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

2.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

Review 3.  Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.

Authors:  Rakesh Dixit; Steve Coats
Journal:  IDrugs       Date:  2009-02

Review 4.  Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates.

Authors:  Anne S De Groot; Julie McMurry; Lenny Moise
Journal:  Curr Opin Pharmacol       Date:  2008-09-19       Impact factor: 5.547

Review 5.  When binding is enough: nonactivating antibody formats.

Authors:  Aran F Labrijn; Rob C Aalberse; Janine Schuurman
Journal:  Curr Opin Immunol       Date:  2008-07-09       Impact factor: 7.486

6.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

Authors:  D Shan; J A Ledbetter; O W Press
Journal:  Cancer Immunol Immunother       Date:  2000-03       Impact factor: 6.968

Review 7.  Monoclonal antibody therapies for solid tumors.

Authors:  Dimiter V Tassev; Nai-Kong V Cheung
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

8.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:  Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 10.  Management of advanced-stage peripheral T-cell lymphomas.

Authors:  Eva Kimby
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 4.213
View more
  28 in total

1.  Conformational Analysis of Proteins in Highly Concentrated Solutions by Dialysis-Coupled Hydrogen/Deuterium Exchange Mass Spectrometry.

Authors:  Damian Houde; Zeinab E Nazari; George M Bou-Assaf; Andrew S Weiskopf; Kasper D Rand
Journal:  J Am Soc Mass Spectrom       Date:  2016-02-09       Impact factor: 3.109

2.  N-terminal α-amino group modification of antibodies using a site-selective click chemistry method.

Authors:  De-Zhi Li; Bing-Nan Han; Rui Wei; Gui-Yang Yao; Zhizhen Chen; Jie Liu; Terence C W Poon; Wu Su; Zhongyu Zhu; Dimiter S Dimitrov; Qi Zhao
Journal:  MAbs       Date:  2018-07       Impact factor: 5.857

3.  Immuno-PET to Optimize the Dose of Monoclonal Antibodies for Cancer Therapy: How Much Is Enough?

Authors:  Raymond M Reilly
Journal:  J Nucl Med       Date:  2019-05-03       Impact factor: 10.057

Review 4.  Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.

Authors:  Weizao Chen; Tianlei Ying; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2013-01-07       Impact factor: 4.388

5.  Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.

Authors:  Sneha Ramakrishna; Steven L Highfill; Zachary Walsh; Sang M Nguyen; Haiyan Lei; Jack F Shern; Haiying Qin; Ira L Kraft; Maryalice Stetler-Stevenson; Constance M Yuan; Jennifer D Hwang; Yang Feng; Zhongyu Zhu; Dimiter Dimitrov; Nirali N Shah; Terry J Fry
Journal:  Clin Cancer Res       Date:  2019-05-20       Impact factor: 12.531

Review 6.  Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer.

Authors:  William C Watt; Denise L Cecil; Mary L Disis
Journal:  Semin Immunopathol       Date:  2016-12-14       Impact factor: 9.623

7.  Rituximab causing deep ulcerative suppurative vaginitis/pyoderma gangrenosum.

Authors:  Priya Selva-Nayagam; Gayle Fischer; Ian Hamann; Jack Sobel; Craig James
Journal:  Curr Infect Dis Rep       Date:  2015-05       Impact factor: 3.725

Review 8.  Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.

Authors:  Benjamin Bonavida
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

Review 9.  Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Authors:  B Bonavida; S Chouaib
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

10.  A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.

Authors:  Ingo Schubert; Domenica Saul; Stefanie Nowecki; Andreas Mackensen; Georg H Fey; Fuat S Oduncu
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.